Navigation Links
Drug Re-Sensitizes Breast Tumors to Treatment
Date:9/5/2008

Phase II study finds sorafenib helps reverse disease resistance to anti-hormonal therapy

FRIDAY, Sept. 5 (HealthDay News) -- The drug sorafenib may help "re-sensitize" certain breast cancer tumors to anti-hormonal drugs, Georgetown University Medical Center researchers say.

Women with estrogen-receptor or progesterone-receptor positive (ER or PR positive) metastatic breast cancers often take anti-hormonal medicines, such as aromatase inhibitors, to keep the cancer under control. Aromatase inhibitors lower the amount of estrogen in the body.

However, the tumor eventually becomes resistant to anti-hormonal drugs, and the cancer begins to grow.

"At first, the tumor's growth is halted, because the aromatase inhibitor is depriving the cancer of the estrogen it needs to grow. Eventually, though, the cancer will figure out another way to thrive in the absence of the estrogen," Dr. Claudine Isaacs, clinical director of the breast cancer program at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center, said in a university news release.

Isaacs and her colleagues wanted to find out if a new approach can restore the effectiveness of anti-hormonal drugs against these tumors.

The phase II study included 27 postmenopausal women with metastatic breast cancer that had recurred or progressed while the women were taking the aromatase inhibitor anastrozole. Preliminary analysis of study data showed that 26 percent of the women showed a clinical benefit response while taking both sorafenib and anastrozole.

"Given what we know about the ineffectiveness of sorafenib alone in metastatic breast cancer, we believe the benefit that we're seeing may be attributable to the restoration of sensitivity to aromatase inhibitors," Isaacs said. "To manage breast cancer long-term, it's apparent that we may need to continually switch drugs to keep up with how a cancer evolves and evades each approach. In a sense, for each step back, we hope to take two steps forward."

The study was to be presented Sept. 5 at the 2008 ASCO Breast Cancer Symposium in Washington, D.C. Isaacs is part of the speaker's bureau for Pfizer Inc., which makes the aromatase inhibitor Exemestane.

More information

The U.S. National Cancer Institute has more about breast cancer treatment.



-- Robert Preidt



SOURCE: Georgetown University Medical Center, news release, Sept. 5, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Breast Cancer Drug Not Tied to Cognitive Decline: Study
2. Hospitals provide formula sample packs while medical organizations encourage breastfeeding
3. Komen Travels to Republican Convention to Raise Awareness of Breast Cancer Issues
4. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
5. Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues
6. Taking Codeine While Breast-Feeding May Harm Infant
7. Breastfeeding, other factors may affect risk of breast cancer type
8. Zoft Breast Enhancement Gum Revolutionizes Breast Enhancement Industry
9. Risk of Breast Cancer Relapse Can Linger
10. Risk assessment plays key role in long-term treatment of breast cancer
11. MedexSupply Announces the Release of the ADC Limited Edition Pink Ribbon Stethoscope, With Proceeds Being Donated to Breast Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; Dr. ... will speak to the press on behalf of over 200 doctors, scientists, and scientific ... commission. , WHERE: , Zenger Room, National Press Club, 529 14th Street NW, ...
(Date:3/28/2017)... ... 2017 , ... Award-winning medical group Allied Anesthesia today announced ... chair for Orange County health care system CalOptima Friday. CalOptima announced its election ... Mark Refowitz’s term, which runs through June 30 of this year, until another ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO ... found in power plant water and steam. , Chlorides and sulfates cause pitting ... leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb ...
(Date:3/28/2017)... ... March 28, 2017 , ... A ... achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is informing ... should be aware of when utilizing dental laboratories and technicians that create these ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice ... Atlantic City March 13-16, was a busy spot this year. Liz Solovay and ... strategies for preventing outbreaks among camp communities during the upcoming 2017 camping season. ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... and TORONTO , March 28, 2017 ... leading full service medical device development firm, announced today ... Toronto -based medical device industrial design ... serve medtech companies throughout North America ... experienced medical device talent spanning the design, engineering, regulatory, ...
(Date:3/28/2017)... United Kingdom and  BOSTON , March 28, ... Linguamatics today announced a partnership with ... The agreement allows pharmaceutical companies to extract key ... I2E text mining technology. The ... of the top 20 global pharmaceutical companies. The ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology: